Turmeric and Curcumin on Sebum Production

Inflammation; Skin Clinical Trial

Official title:

Pilot Study on the Effects of Oral Curcumin and Turmeric on Sebum Production

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03066791
• Other study ID #: 850932
• Status: Completed
• Phase: N/A
• Start date: November 30, 2016
• Est. completion date: August 28, 2017

Study information

• Verified date: December 2018
• Source: University of California, Davis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A noticeably increasing number of patients are asking for naturally based extracts and ingredients as supplementary dermatologic remedies. Patients are seeking natural and cost-effective skin care alternatives in place of prescription medications and procedures. Our study will evaluate the effects of oral curcumin and turmeric on sebum production in healthy subjects.

Description:

Turmeric extracts and curcumin have been shown to be safe, even at high doses without significant side-effects. Previous clinical studies in other inflammatory skin diseases have shown that a dosage of curcumin at 6,000 mg daily was effective while lower doses were not. In a human phase I clinical trial examining the effects of high dose curcumin in preventing premalignant lesions, even curcumin doses as high as 8,000 mg/day resulted in no toxic effects after 3 months. This study will involve participant ingestion of 6,000 mg/day of turmeric or curcumin to assess how this affects their sebum production.

The investigators will also be collecting stool from the study subjects, and examining how the curcumin and turmeric may modulate their gut microbiome. The investigators will specifically be looking to see if curcumin or turmeric have any changes on the gut flora towards bacteria that produce more short chain fatty acids. Certain bacteria that make up the microbiome produce short chain fatty acids, such as butyrate and propionate, which have demonstrated anti-inflammatory properties. Thus, it would be interesting to see if turmeric or curcumin exert any of its anti-inflammatory effects via modulation of the microbiome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 28, 2017
• Est. primary completion date: August 28, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Age 18 to 50 years of age, and

2. Subject must be able to read and comprehend study procedures and consent forms.

Exclusion Criteria:

1. Subject should be generally healthy and have no smoking history in the past one year, and must have no history of diabetes, metabolic syndrome, known cardiovascular disease, malignancy, kidney disease, or chronic steroid use.

2. Those who used topical medications in the past two weeks or systemic antibiotics or oral probiotics within one month of starting the study.

3. Subjects who are postmenopausal

4. Those who are pregnant or breastfeeding.

5. Those that are prisoners or cognitively impaired.

6. Those who have a known allergy to black pepper should not participate in this clinical trial, since one of the treatments consists of tablets containing a small amount (1.25mg/tablet) of black pepper.

7. Those that are taking angiotensin converting enzyme inhibitor medications or angiotensin receptor blocker medications for any reason.

Related Conditions & MeSH terms

• Dermatitis
• Inflammation
• Inflammation; Skin

Intervention

Dietary Supplement:
• Turmeric tablets

• Curcumin and Bioperine tablets

• Placebo tablets

Locations

Country	Name	City	State
United States	University of California, Davis Dermatology Clinical Trials Unit	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

References & Publications (2)

Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003 Feb;9(1):161-8. Review. — View Citation

Thangapazham RL, Sharma A, Maheshwari RK. Beneficial role of curcumin in skin diseases. Adv Exp Med Biol. 2007;595:343-57. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sebum production	Sebutapes will be used to measure sebum production at each visit. The sebutapes will then be collected and analyzed for fatty acids and lipid production.	8 weeks
Secondary	Change from Baseline in Sebum profile, such as inflammatory markers at 8 weeks		8 weeks
Secondary	Change in stool microbiome diversity (optional collections for subjects) from baseline at 8 weeks		8 weeks